Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma

Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim

Clin Mol Hepatol. 2024;30(3):360-374. Published online March 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0042

View: 1588 Download: 195 Crossref: 1

Correspondence

Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression”

Sungju Jung, Sumin Yoon, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo

Clin Mol Hepatol. 2024;30(2):287-290. Published online February 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0136

View: 1707 Download: 48

Original Article

Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression

Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo

Clin Mol Hepatol. 2024;30(2):247-262. Published online January 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0449

View: 2882 Download: 201 Web of Science: 2 Crossref: 2

Editorial

The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective

Carlos Jose Pirola, Silvia Sookoian

Clin Mol Hepatol. 2024;30(2):174-176. Published online February 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0082

View: 1938 Download: 59 Web of Science: 1 Crossref: 1

Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?

Heejoon Jang, Won Kim

Clin Mol Hepatol. 2023;29(2):381-383. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0088

View: 2847 Download: 85 Web of Science: 2 Crossref: 3

Snapshot

Microbiome and metabolomics in alcoholic liver disease

Raja Ganesan, Ki Tae Suk

Clin Mol Hepatol. 2022;28(3):580-582. Published online July 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0171

View: 4889 Download: 157 Web of Science: 5 Crossref: 6

Review

Radiomics and radiogenomics of primary liver cancers

Woo Kyoung Jeong, Neema Jamshidi, Ely Richard Felker, Steven Satish Raman, David Shinkuo Lu

Clin Mol Hepatol. 2019;25(1):21-29. Published online November 16, 2018

DOI: https://doi.org/10.3350/cmh.2018.1007

View: 12564 Download: 408 Web of Science: 44 Crossref: 48

The mutational landscape of hepatocellular carcinoma

Ju-Seog Lee

Clin Mol Hepatol. 2015;21(3):220-229. Published online September 30, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.3.220

View: 14355 Download: 385 Web of Science: 92 Crossref: 85

3

Protein Expression Profiles in a Rat Cirrhotic Model Induced by Thioacetamide

Jeung Hee An, Ph.D. Jinsil Seong, M.D. Haejin Oh, M.S. Wonwoo Kim, M.S. Kwang-Hyub Han, M.D. and Yong Han Paik, M.D.

Clin Mol Hepatol. 2006;12(1):93-102. Published online January 1, 1970

View: 2953 Download: 34

1 |

Viewed By 5505	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5406	MAFLD: How is it different from NAFLD?
Viewed By 5215	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5095	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4727	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search